Single-dose levilimab safe and effective in severe COVID-19

Key clinical point: A single subcutaneous dose of levilimab (LVL) was safe and effective in severely ill patients with COVID-19 not requiring mechanical ventilation.

Major finding: 63.1% of patients in the LVL group vs 42.7% in the placebo group achieved sustained clinical improvement on day 14 (P = .0017). Adverse event frequency was comparable between the groups.

Study details: In the phase 3 CORONA trial, 206 patients were randomly assigned (1:1) to receive either LVL+standard of care (SOC) vs placebo+SOC.

Disclosures: This study was funded by JSC BIOCAD. MY Gilyarov reported ties with various pharmaceutical companies. AI Seleznev, YN Linkova, EA Dokukina, PS Pukhtinskaia, AV Eremeeva, MA Morozova, AV Zinkina-Orikhan, and AA Lutckii are employees of JSC BIOCAD.

Source: Lomakin NV et al. Inflamm Res. 2021 Sep 29. doi: 10.1007/s00011-021-01507-5.

Key clinical point: A single subcutaneous dose of levilimab (LVL) was safe and effective in severely ill patients with COVID-19 not requiring mechanical ventilation.

Major finding: 63.1% of patients in the LVL group vs 42.7% in the placebo group achieved sustained clinical improvement on day 14 (P = .0017). Adverse event frequency was comparable between the groups.

Study details: In the phase 3 CORONA trial, 206 patients were randomly assigned (1:1) to receive either LVL+standard of care (SOC) vs placebo+SOC.

Disclosures: This study was funded by JSC BIOCAD. MY Gilyarov reported ties with various pharmaceutical companies. AI Seleznev, YN Linkova, EA Dokukina, PS Pukhtinskaia, AV Eremeeva, MA Morozova, AV Zinkina-Orikhan, and AA Lutckii are employees of JSC BIOCAD.

Source: Lomakin NV et al. Inflamm Res. 2021 Sep 29. doi: 10.1007/s00011-021-01507-5.

Key clinical point: A single subcutaneous dose of levilimab (LVL) was safe and effective in severely ill patients with COVID-19 not requiring mechanical ventilation.

Major finding: 63.1% of patients in the LVL group vs 42.7% in the placebo group achieved sustained clinical improvement on day 14 (P = .0017). Adverse event frequency was comparable between the groups.

Study details: In the phase 3 CORONA trial, 206 patients were randomly assigned (1:1) to receive either LVL+standard of care (SOC) vs placebo+SOC.

Disclosures: This study was funded by JSC BIOCAD. MY Gilyarov reported ties with various pharmaceutical companies. AI Seleznev, YN Linkova, EA Dokukina, PS Pukhtinskaia, AV Eremeeva, MA Morozova, AV Zinkina-Orikhan, and AA Lutckii are employees of JSC BIOCAD.

Source: Lomakin NV et al. Inflamm Res. 2021 Sep 29. doi: 10.1007/s00011-021-01507-5.